H.C. Wainwright Lifts PT on Ocular Therapeutix (OCUL) to $19 From $15, Keeps a Buy Rating

Group 1 - Ocular Therapeutix Inc. (NASDAQ:OCUL) is recognized as a promising healthcare stock with significant upside potential, receiving a price target increase from H.C. Wainwright to $19 from $15 while maintaining a Buy rating [1][2] - The price target adjustment follows the FDA granting a Special Protocol Assessment (SPA) for Ocular Therapeutix's AXPAXLI, aimed at treating non-proliferative diabetic retinopathy (NPDR) [2][3] - The company presented the design of two Phase 3 superiority trials, HELIOS-2 and HELIOS-3, during its investor day, which are critical for the evaluation of AXPAXLI [2][3] Group 2 - HELIOS-2 is a two-arm trial comparing a single AXPAXLI injection to a single ranibizumab injection, while HELIOS-3 is a three-arm trial comparing two dosing regimens of AXPAXLI to a sham treatment [3] - The updated financial model anticipates potential sales of AXPAXLI in NPDR, projecting the company's market value at $3.97 billion, equating to $19 per share [3] - Ocular Therapeutix is a biopharmaceutical company focused on developing therapies for eye-related conditions, with a product pipeline that includes Dextenza, OTX-TP, and OTX-TIC [4]